Immunovia

187 articles about Immunovia

• Immunovia publishes the annual report for 2022

  4/21/2023

  Immunovia AB (publ) today announced that the Annual Report for 2022 has been published. 

• Immunovia to participate in National Pancreas Foundation Webinar on Biomarkers and Liquid Biopsy for Early Detection of Pancreatic Cancer

  4/20/2023

  Immunovia announced it will participate in a webinar titled "Biomarkers and Liquid Biopsy for Early Detection of Pancreatic Cancer" hosted by the National Pancreas Foundation on April 26, 2023, at 7:00 pm ET.

• Bulletin from the extraordinary general meeting in Immunovia AB

  3/16/2023

  On 16th March 2023, an extraordinary general meeting was held in Immunovia AB, 556730-4299 at The Spark, Scheeletorget 1, Medicon Village, in Lund.

• Immunovia appoints Karl Stone as new chief operating officer to develop R&D and operations

  3/1/2023

  Immunovia, the diagnostics company that has launched the world's first blood-based test dedicated to the early detection of pancreatic cancer, announced the appointment of Karl Stone as Chief Operating Officer effective 1 March, 2023.

• Immunovia Publishes Full Year Report for 2022

  2/23/2023

  In Q4, Immunovia continued to execute on its unique position as a leader in innovative early detection of pancreatic cancer.

• Convening Notice - Extraordinary General Meeting in Immunovia AB (publ)

  2/20/2023

  Immunovia AB, reg. no. 556730-4299, hereby gives notice that an Extraordinary General Meeting will take place on Thursday 16th March 2023 at 10.00 at The Spark, Scheeletorget 1, Medicon Village, in Lund.

• Invitation to Immunovia's Q4 presentation

  2/20/2023

  Immunovia will publish its full year 2022 results on February 23, 2023 at 8:30 am CET.

• Immunovia - Consultation process with Swedish unions completed

  2/8/2023

  Immunovia announced that the consultation process regarding realigning its Swedish operations, announced on 19 January 2023, has been completed.

• Immunovia realigning Swedish operations with strategic priorities and its focus on the US commercialization of the IMMray™ PanCan-d test

  1/19/2023

  Immunovia announced it is realigning its Swedish operations with its strategic priorities to drive R&D productivity and focus on the US commercialization of the IMMray™ PanCan-d test.

• Immunovia announces updated financial calendar for financial year 2023

  1/19/2023

  Immunovia, a diagnostic company with the vision to revolutionize blood-based diagnostics and survival rates for patients with cancer, announces its financial calendar for 2023 and 2024.

• Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray™ PanCan-d test in the US market

  1/17/2023

  Immunovia announced that it has appointed Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs effective February 1, 2023.

• Immunovia strengthens US organization to continue commercialization of its novel IMMray™ PanCan-d test

  12/5/2022

  Immunovia, the diagnostics company that has launched the world's first blood test dedicated to the early detection of pancreatic cancer, announced that its U.S. subsidiary, Immunovia Inc., has appointed a new National Sales Director.

• Centers for Medicare & Medicaid Services finalizes its payment determination and sets a rate of $897 for Immunovia's IMMray PanCan-d test

  11/30/2022

  Immunovia announced that the Centers for Medicare and Medicaid Services has finalized their payment determination on a price of $897 for Immunovia's IMMray PanCan-d test.

• Chief Executive Offier, Philipp Mathieu, buys Immunovia warrants

  11/16/2022

  Immunovia AB announces that Philipp Mathieu, CEO of Immunovia, has purchased 150000 warrants of the 2022/2026 scheme for approximately 297 KSEK.

• Immunovia announces the financial calendar for financial year 2023

  11/11/2022

  Immunovia announces its financial calendar for 2023 and 2024.

• Immunovia Publishes Interim Report Jan-Sep 2022

  11/10/2022

  Q3 has been a quarter focussed on commercial execution and taking further steps towards reimbursement to make our innovative IMMRay PanCan-d test, the first dedicated test for early detection of pancreatic cancer, broadly available in the US.

• Invitation to Immunovia's Q3 presentation

  11/3/2022

  Immunovia will publish its third quarter 2022 results on November 10, 2022 at 8:30 am CET.

• Nomination Committee appointed for the 2023 Annual General Meeting of Immunovia AB (Publ)

  10/20/2022

  According to the instructions for the Nomination Committee of Immunovia AB that were adopted at the Annual General Meeting on April 7, 2022, the Nomination Committee shall consist of four members.

• Immunovia announces executive management team changes to accelerate execution of strategic priorities

  10/19/2022

  Immunovia AB announced changes to its executive management team to accelerate the execution of its strategic priorities.

• Immunovia launches a strategic partnership with Proteomedix to leverage R&D efforts with increased focus on commercialization

  10/17/2022

  Immunovia AB announced that it enters into a strategic partnership with Proteomedix to leverage its substantial joint development experience in diagnostic technologies for the detection of cancer.